Drug Trial Radar · NCT07283770
Evaluation of VX-581 in Healthy Participants and in Participants With Cystic Fibrosis
Last checked: Nov 20, 2026Latest source record: Oct 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
152
Planned (sponsor's estimate)
Start
Dec 9, 2025
Primary completion
Jul 12, 2027
Study completion Jul 12, 2027
Sponsor
- Lead sponsor
- Vertex Pharmaceuticals IncorporatedVertex Pharmaceuticals (VRTX)
- Sponsor type
- Industry
- First posted
- Dec 16, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of single dose of VX-581 and multiple ascending doses of VX-581 alone and in combination with tezacaftor (TEZ)/deutivacaftor (D-IVA) or D-IVA in healthy participants. The study will also evaluate the safety, tolerability, and pharmacokinetics of VX-581 administered in combination with D-IVA with or without TEZ in participants with cystic fibrosis (CF).
Conditions
- Cystic Fibrosis
Interventions
VX-581Drug
Suspension for Oral Administration.
PlaceboDrug
Suspension for Oral Administration.
D-IVADrug
Tablet for Oral Administration.
TEZDrug
Tablet for Oral Administration.
ELX/TEZ/IVADrug
Fixed dose combination (FDC) Tablets for Oral Administration.
VX-581Drug
Tablets for Oral Administration.
IVADrug
Tablet for Oral Administration.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part A: Safety and Tolerability as Assessed by Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)Time frame: From Day -1 up to Day 8
- Part B: Safety and Tolerability as Assessed by Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)Time frame: From Day -1 up to Day 17
- Part C: Safety and Tolerability as Assessed by Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)Time frame: From Day -1 up to Day 17
- Part D: Safety and Tolerability as Assessed by Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)Time frame: From Signing of Informed Consent up to Day 105
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Altasciences - Kansas City
Overland Park, Kansas · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.